1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Hyloris Partner Signs To Market Maxigesic IV In Central And Eastern Europe

Hyloris Has Also In-Licensed A Blood Mineral Deficiency Drug

 
• By Rosalind Rei

Hyloris’ partner AFT has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals covering nine central and eastern European countries. Meanwhile, Hyloris has also struck an in-licensing deal for a new blood phosphorus deficiency treatment. 

Hyloris continues its European rollout for Maxigesic IV • Source: Shutterstock

Hyloris’ partner AFT Pharmaceuticals has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals for Maxigesic IV, covering multiple central and eastern European markets.

The drug is a non-opioid intravenous pain treatment co-owned by Hyloris

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business